Wellington Management Group LLP Has $2.06 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Wellington Management Group LLP lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 99.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,685 shares of the medical research company's stock after selling 1,615,529 shares during the period. Wellington Management Group LLP's holdings in IQVIA were worth $2,058,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in IQV. Weiss Asset Management LP acquired a new stake in IQVIA in the third quarter valued at $6,840,000. Two Sigma Advisers LP increased its holdings in IQVIA by 206.8% in the third quarter. Two Sigma Advisers LP now owns 108,600 shares of the medical research company's stock valued at $25,735,000 after buying an additional 73,200 shares during the last quarter. Quantinno Capital Management LP raised its stake in IQVIA by 82.0% during the third quarter. Quantinno Capital Management LP now owns 18,059 shares of the medical research company's stock valued at $4,280,000 after buying an additional 8,138 shares in the last quarter. Point72 DIFC Ltd increased its holdings in shares of IQVIA by 199.5% in the 3rd quarter. Point72 DIFC Ltd now owns 2,289 shares of the medical research company's stock valued at $542,000 after acquiring an additional 4,589 shares during the last quarter. Finally, Investment Management Corp of Ontario lifted its stake in IQVIA by 49.4% during the third quarter. Investment Management Corp of Ontario now owns 6,049 shares of the medical research company's stock worth $1,433,000 after purchasing an additional 2,000 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on IQV shares. Barclays decreased their price target on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a report on Wednesday, December 11th. Evercore ISI lowered their price objective on IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. The Goldman Sachs Group cut their target price on IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and an average target price of $256.19.

IQVIA Price Performance

Shares of NYSE:IQV traded up $0.55 on Thursday, reaching $191.52. 1,901,188 shares of the company traded hands, compared to its average volume of 1,195,767. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a market capitalization of $34.76 billion, a PE ratio of 25.13, a P/E/G ratio of 2.05 and a beta of 1.49. The company's 50 day moving average is $210.32 and its 200-day moving average is $223.64. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.